Real-World study tests Trimbow's impact on severe COPD symptoms

NCT ID NCT07406048

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking about 400 adults with severe or very severe COPD in Brazil who are taking the triple-combination inhaler Trimbow. Researchers will measure changes in symptoms and lung function over 6 months during routine doctor visits. The goal is to see how well the medication works in everyday practice, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Trimbow (a triple combination inhaler containing beclometasone, formoterol, and glycopyrronium)
What this could lead to
If successful, this study could confirm that Trimbow helps control symptoms and reduce flare-ups in people with severe COPD in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also relatively small and short-term, so findings may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Santa Casa de Misericórdia de São Paulo

    RECRUITING

    São Paulo, São Paulo, 01221-020, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.